Clinical Insights

More

Sanofi’s Orphan Drug Supply Update | The CheckRare Brief Special Edition

On this special edition of the CheckRare Brief, we talk with Alaa Hamed, Sanofi's Global Head of Medical Affairs for Rare Diseases, and Maite Durrenbach, Head of Specialty Care Manufacturing and...

Highlights from The Liver Meeting 2026 | The CheckRare Brief

In this episode, we discuss highlights from The Liver Meeting, Ultragenyx program cuts, and ANI Pharmaceuticals’ offer to buy Egetis Therapeutics.     Ultragenyx Ends Angelman Syndrome and...

3D Printed Treatment Options | The CheckRare Brief

In this episode, we discuss a new formulation of treatment for HAE, the FDA approval of Voceryq for recurrent respiratory papillomatosis, and 3D printed treatment options.       New...

Organoids and Lab-Grown Models in Lysosomal Disorders

Organoids and Lab-Grown Models in Lysosomal Disorders

Mia Horowitz, PhD, Aitor Aguirre, PhD, and Ying Sun, PhD, discuss the use of organoid models in lysosomal disorder research and drug development.

Recent Videos

Social Wall

Vinoid Ravi MD, MS, MBA, discusses new data on Pimicotinib for Tenosynovial Giant Cell Tumors

Laura Hameed, IRSF CEO, discusses the inclusion of males in clinical trials for Rett Syndrome

What’s new in generalized myasthenia gravis (gMG)? 🧬

CheckRare highlights key research and treatment updates from the 2026 AANEM Annual Meeting, exploring advances that may help inform gMG management and patient care.

🎥 Watch the full video for expert insights.

Read more🔗 Explore

On this special edition of the CheckRare Brief, we talk with Alaa Hamed, Sanofi’s Global Head of Medical Affairs for Rare Diseases, and Maite Durrenbach, Head of Specialty Care Manufacturing and Supply at Sanofi, about the company’s current supply chain problems for some of their

Laura Hameed, CEO, and Dominique Pichard, MD, MS, CSO/CMO of the @Rettsyndrome, discuss the changing treatment landscape for Rett syndrome and the organization’s commitment to supporting patients and their families.

International Rett Syndrome Foundation Works to Advance Research and Support Families

International Rett Syndrome Foundation Works to Advance Research and Support Families

Three-Year Study Finds Burosumab Improves Symptoms in Adults With X-Linked Hypophosphatemia

Three-Year Study Finds Burosumab Improves Symptoms in Adults With X-Linked Hypophosphatemia

Dr. Joshua Zeidner explains the REVEAL-ND clinical trial enrolling patients with newly diagnosed, previously untreated NPM1-mutated AML.

For more information on trial design, enrollment, and outcomes, view the full interview at Read morehttps://checkrare.com/revumenib-chemotherapy-in-newly-diagnosed-aml-with-npm1-mutation-phase-3-reveal-nd-study/

#AML #AcuteMyeloidLeukemia